AMPK Phosphorylation-Blocking Peptides for Metabolic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mitochondrial dysfunction leads to impaired nutrient metabolism and contributes to metabolic disorders and cancer, with the molecular mechanisms underlying this impairment not well understood, particularly involving the phosphorylation of AMPKα1S496 and AMPKα2S491 by AKT or PKA, leading to impaired AMPK-MFF-DRP1 signaling and reduced mitochondrial oxidative activity.
Innovation Solution
Development of peptides that specifically block the phosphorylation of AMPKα1S496 and/or AMPKα2S491, enhancing mitochondrial oxidative activity, promoting mitochondrial fission, and eliminating compromised mitochondria, thereby improving metabolic function and inhibiting tumor cell growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AMPKα1S496 and AMPKα2S491 are phosphorylated by AKT or PKA, then insulin signaling and glucose metabolism are regulated, but mitochondrial oxidative activity is impaired and mitochondrial fission is reduced
Solution Approach 1:
The patent introduces peptides (Pa496h, Pa496m, Pa2-491) as intermediary substances that specifically block the phosphorylation of AMPKα1S496 and AMPKα2S491 by AKT or PKA. These peptides act as mediators to prevent the harmful phosphorylation event while preserving the beneficial insulin signaling pathway, thereby resolving the contradiction between maintaining insulin regulation and preserving mitochondrial oxidative activity.
Solution Approach 2:
The patent changes the phosphorylation state parameter of AMPKα1S496 and AMPKα2S491 from phosphorylated to non-phosphorylated by using blocking peptides. This parameter change restores mitochondrial oxidative activity and promotes mitochondrial fission while maintaining insulin signaling regulation, thus resolving the contradiction between these two functions.
2Adaptability or versatility
If AMPKα1S496 and AMPKα2S491 are phosphorylated by AKT or PKA, then metabolic signaling is modulated, but AMPK-MFF-DRP1 signaling is impaired and mitochondrial dynamics are reduced
Solution Approach 1:
The blocking peptides serve as intermediary substances that specifically interfere with the phosphorylation of AMPKα1S496 and AMPKα2S491. By preventing this specific phosphorylation event, the peptides preserve the integrity of the AMPK-MFF-DRP1 signaling pathway and mitochondrial dynamics while still allowing metabolic signaling modulation through other AMPK activation mechanisms.
Solution Approach 2:
The patent segments the AMPK regulation into distinct functional domains: the blocking of S496/S491 phosphorylation preserves mitochondrial dynamics, while separate AMPK activation pathways maintain metabolic signaling. This segmentation allows independent optimization of both functions without interference.
3Shape
If mitochondrial fission is downregulated by AMPK phosphorylation, then mitochondrial morphology is maintained, but nutrient metabolism is impaired and aging-related diseases occur
Solution Approach 1:
The patent changes the phosphorylation parameter of AMPKα1S496 and AMPKα2S491 from phosphorylated to non-phosphorylated state using blocking peptides. This parameter change restores mitochondrial fission and nutrient metabolism while allowing mitochondrial morphology to be dynamically regulated by other pathways, thus resolving the contradiction between morphology maintenance and metabolic productivity.
Solution Approach 2:
The patent restores dynamic mitochondrial fission by blocking the inhibitory phosphorylation of AMPK. This allows mitochondria to dynamically adjust their morphology and number in response to metabolic demands, improving nutrient metabolism while maintaining the ability to adapt mitochondrial shape and distribution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides increase mitochondrial respiration, reduce ROS production, and maintain healthy mitochondria populations, effectively treating or preventing metabolic disorders such as diabetes and obesity, and inhibiting the growth of cancer cells, including hepatocellular carcinoma and breast cancer.
Implementation Method 1
inhibitors of phosphorylation of AMPKalpha1 at Serine496 and AMPKalpha2 at S491
Implementation Method 2
increase AMPK kinase activity and fragmentation of elongated mitochondria
Implementation Method 3
fragmentation of elongated mitochondria
Implementation Method 4
improve mitochondrial oxidative activity, reduce ROS
Data Source
AI summary
Provided herein are compositions and methods for treating or preventing metabolic disorders and cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of phosphorylation of AMPKalpha1 at Serine496 and AMPKalpha2 at S491 for improving metabolic function and treating and preventing metabolic diseases (e.g., diabetes and obesity) and cancer (e.g., hepatocellular carcinoma and breast cancer).